10-K: Pluri Inc. Outlines Securities, Business Strategy and Financial Results in Annual 10-K Filing

Pluri Inc.'s annual 10-K filing details its authorized securities, business operations across multiple sectors, and financial performance for the fiscal year ended June 30, 2024.

Summary

• Pluri Inc. is a biotechnology company focused on cell-based technology, with operations in regenerative medicine, immunotherapy, food tech, CDMO, and agtech.
• The company is authorized to issue 37,500,000 shares of common stock and 1,000,000 shares of preferred stock, both with a par value of $0.00001 per share.
• Pluri's common stock is listed on the Nasdaq Capital Market under the symbol PLUR.
• The company's technology platform includes a patented 3D cell expansion system for large-scale cell manufacturing.
• Pluri's cell therapy pipeline includes PLX-PAD and PLX-R18 cells, and a novel allogeneic immunotherapy platform utilizing MAIT cells.
• The company launched PluriCDMO in January 2024, offering cell therapy manufacturing services.
• Pluri is also involved in agtech initiatives, including cell-based coffee and collaborations to enhance bio stimulant delivery and vegetable supply.
• In food tech, Pluri has a joint venture, Ever After Foods, focused on developing cultivated meat products.
• For the fiscal year ended June 30, 2024, Pluri reported revenues of $326,000 and a net loss of $21,344,000.
• Research and development expenses decreased by 21% to $12,446,000, and general and administrative expenses decreased by 15% to $10,034,000.
• The company had a working capital surplus of $26,653,000 as of June 30, 2024.
• Pluri has received grants from the IIA, the European Union's Horizon program, and the NIH, among others.
• The company is subject to various risks, including the need for additional capital, competition, and regulatory hurdles.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in technology, partnerships, and cost reduction, the company's ongoing losses, need for capital, and various risks temper the overall sentiment. The company is still in a high-risk phase.

Positives

• Pluri has a diverse portfolio of cell-based technologies with applications in multiple industries.
• The company has secured significant non-dilutive funding through grants and collaborations.
• Pluri has a strong intellectual property portfolio with numerous issued and pending patents.
• The company has an in-house GMP cell manufacturing facility, which is approved by multiple regulatory agencies.
• Pluri has demonstrated a reduction in operating expenses and net loss compared to the previous year.
• The company has a working capital surplus of $26,653,000 as of June 30, 2024.
• Pluri has established strategic partnerships and collaborations to expand its business reach.

Negatives

• Pluri has a history of losses and has not generated significant revenues to date.
• The company may need to raise additional capital to meet its business requirements.
• Pluri is exposed to various global and local risks that could have a material adverse effect on its financial condition.
• The market prices of Pluri's common shares are subject to fluctuation and have been volatile.
• The company is subject to fluctuations in currency exchange rates.
• Restrictions contained in the EIB Finance Agreement may limit Pluri's ability to conduct certain strategic initiatives.
• Pluri has a limited operating history in the field of food tech, agtech, and CDMO.
• The company could fail to maintain the listing of its common shares on Nasdaq.

Risks

• Pluri may need to raise additional capital, which may be costly or difficult to obtain and could dilute shareholders' ownership.
• The company may become subject to claims by competitors enforcing their IP rights.
• There are inherent risks in the manufacturing of Pluri's product candidates, including meeting regulatory standards.
• If Pluri is unable to obtain and maintain IP protection, others may be able to utilize its IP.
• The company is exposed to various global and local risks that could have a material adverse effect on its financial condition.
• Cybersecurity incidents may have an adverse impact on Pluri's business and operations.
• Recent increasing global inflation could affect Pluri's ability to purchase materials and increase costs.
• There are risks relating to Pluri's CDMO business, including financial risks associated with contracts.
• There are risks relating to Pluri's food-tech endeavors, including changes in consumer preferences and governmental regulations.
• The research and development associated with technologies for cultivated meat manufacturing is a lengthy and complex process.
• Pluri could fail to maintain the listing of its common shares on Nasdaq.

Future Outlook

Pluri expects to generate revenues from the sale of services in its CDMO activity, from collaborations based on its cell-based products, and from licenses to use its technology and products. The company believes it has sufficient cash to fund operations for at least the next twelve months, but may require additional liquidity resources to support commercialization and research activities.

Management Comments

• Management believes that its current resources together with its existing operating plan, are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these consolidated financial statements.
• Management expects that the Company will incur additional losses as it continues to focus its resources on advancing research and development activities as well as commercial operations, which will result in negative cash flows from operating activities.

Industry Context

Pluri operates in the competitive biotechnology and pharmaceutical industries, facing competition from both allogeneic and autologous cell therapy companies, as well as academic and research institutions. The company is also navigating the evolving regulatory landscape for cultivated meat and cell-based coffee.

Comparison to Industry Standards

• Pluri's focus on allogeneic cell therapies aligns with a growing trend in the regenerative medicine field, where off-the-shelf products are gaining traction.
• The company's 3D cell expansion technology is a differentiator, as many competitors rely on traditional bioreactor methods.
• Pluri's entry into the CDMO space is similar to other companies like Lonza Group AG, AGC Biologics A/S and Charles River Laboratories International, Inc., but Pluri is focused on cell therapy manufacturing.
• In the cultivated meat sector, Ever After Foods competes with companies like Upside Foods, Believer Meats, and GOOD Meat, but aims to differentiate itself with a B2B technology platform.
• Pluri's agtech initiatives, including cell-based coffee, are in a nascent market with competitors like California Cultured Inc. and Ayana Bio LLC.
• The company's financial results show a reduction in net loss and operating expenses, which is a positive trend compared to previous years, but the company still needs to achieve profitability.

Management Changes

Stakeholder Impact

• Shareholders face the risk of dilution from potential future capital raises.
• Employees may be affected by cost reduction measures and potential changes in the company's direction.
• Customers of PluriCDMO will benefit from the company's cell therapy manufacturing services.
• Partners and collaborators will be impacted by the company's ability to execute its business strategy.
• Creditors are exposed to the company's financial performance and ability to repay debts.

Next Steps

• Pluri will continue to focus on advancing its research and development activities.
• The company will seek to expand its CDMO business and secure additional clients.
• Pluri will continue to develop its cell-based products and technologies.
• The company will explore additional partnerships, joint ventures, and licensing opportunities.
• Pluri will work to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

cell therapy, regenerative medicine, immunotherapy, food tech, agtech, CDMO, 3D cell expansion, PLX cells, MAIT cells, biotechnology, patents, clinical trials, manufacturing, intellectual property, financial results